Oncolytics rises on additional data for pelareorep in colorectal cancer
Source: SeekingAlpha
2025-12-16 11:21:36 ET
More on Oncolytics Biotech
- Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer
- Oncolytics Biotech entered into $50M at-the-market sales agreement with BTIG
- Seeking Alpha’s Quant Rating on Oncolytics Biotech
- Historical earnings data for Oncolytics Biotech
- Financial information for Oncolytics Biotech
Read the full article on Seeking Alpha
For further details see:
Oncolytics rises on additional data for pelareorep in colorectal cancer
Oncolytics Biotech Inc.
NASDAQ: ONCY
ONCY Trading
-5.91% G/L:
$0.91 Last:
438,923 Volume:
$0.95 Open:
ONCY Latest News
June 02, 2026 09:00:00 am
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
June 01, 2026 09:00:00 am
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
ONCY Stock Data
$91,131,840
106,702,482
13.96%
27
N/A
Biotechnology & Life Sciences
Healthcare
CA
San Diego
